JP2018168176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018168176A5 JP2018168176A5 JP2018125703A JP2018125703A JP2018168176A5 JP 2018168176 A5 JP2018168176 A5 JP 2018168176A5 JP 2018125703 A JP2018125703 A JP 2018125703A JP 2018125703 A JP2018125703 A JP 2018125703A JP 2018168176 A5 JP2018168176 A5 JP 2018168176A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- configuration
- subject
- actrii inhibitor
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710024845 ACVR2A Proteins 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 208000003432 Bone Disease Diseases 0.000 description 7
- 208000006445 Chronic Kidney Disease-Mineral and Bone Disorder Diseases 0.000 description 5
- 210000000988 Bone and Bones Anatomy 0.000 description 4
- 206010029151 Nephropathy Diseases 0.000 description 3
- 206010038428 Renal disease Diseases 0.000 description 3
- 208000005475 Vascular Calcification Diseases 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 201000005991 hyperphosphatemia Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 208000009863 Chronic Kidney Failure Diseases 0.000 description 1
- 208000005368 Osteomalacia Diseases 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000003143 atherosclerotic Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
Description
本明細書に言及された全ての刊行物、特許、及び特許出願は、各々の個々の刊行物、特許、又は特許出願が、その全体として引用により具体的かつ個別に組み込まれることが示される場合と同じ程度に、引用により本明細書中に組み込まれる。
本件出願は、以下の構成の発明を提供する。
（構成１）
対象における低回転型骨障害を治療する方法であって、治療有効量のActRIIインヒビターを、該低回転型骨障害の治療を必要とする対象に投与することを含む、前記方法。
（構成２）
対象における低回転型骨障害形態のCKD-MBDを治療する方法であって、治療有効量のActRIIインヒビターを、該低回転型骨障害形態のCKD-MBDの治療を必要とする対象に投与することを含む、前記方法。
（構成３）
前記低回転型骨障害が、石灰化した骨へのテトラサイクリン取込みの欠如を特徴とする、構成1又は2記載の方法。
（構成４）
対象における低骨代謝回転形態のCKD-MBDを治療する方法であって、治療有効量のActRIIインヒビターを、該低骨代謝回転形態のCKD-MBDの治療を必要とする対象に投与することを含む、前記方法。
（構成５）
前記低骨代謝回転形態のCKD-MBDが骨軟化症である、構成4記載の方法。
（構成６）
対象における高リン血症を特徴とする骨障害を治療する方法であって、治療有効量のActRIIインヒビターを、該高リン血症を特徴とする骨障害の治療を必要とする対象に投与することを含む、前記方法。
（構成７）
対象における血管石灰化を治療する方法であって、治療有効量のActRIIインヒビターを、アテローム性動脈硬化性石灰化の治療を必要とする対象に投与することを含む、前記方法。
（構成８）
対象における腎疾患を治療する方法であって、治療有効量のActRIIインヒビターを、該腎疾患の治療を必要とする対象に投与することを含む、前記方法。
（構成９）
前記腎疾患が腎線維症である、構成8記載の方法。
（構成１０）
血管石灰化を有すると診断された対象における血管内カルシウムレベルを低下させる方法であって、治療有効量のActRIIインヒビターを該対象に投与することを含む、前記方法。
（構成１１）
前記ActRIIインヒビターが:
a.配列番号2と90％同一のもの;
b.配列番号2と95％同一のもの;
c.配列番号2と98％同一のもの;
d.配列番号2;
e.配列番号3と90％同一のもの;
f.配列番号3と95％同一のもの;
g.配列番号3と98％同一のもの;
h.配列番号3;
i.配列番号6と90％同一のもの;
j.配列番号6と95％同一のもの;
k.配列番号6と98％同一のもの;
l.配列番号6;
m.配列番号7と90％同一のもの;
n.配列番号7と95％同一のもの;
o.配列番号7と98％同一のもの;
p.配列番号7;
q.配列番号12と90％同一のもの;
r.配列番号12と95％同一のもの;
s.配列番号12と98％同一のもの;
t.配列番号12;
u.配列番号17と90％同一のもの;
v.配列番号17と95％同一のもの;
w.配列番号17と98％同一のもの;
x.配列番号17;
y.配列番号20と90％同一のもの;
z.配列番号20と95％同一のもの;
aa.配列番号20と98％同一のもの;
bb.配列番号20;
cc.配列番号21と90％同一のもの;
dd.配列番号21と95％同一のもの;
ee.配列番号21と98％同一のもの;
ff.配列番号21
gg.配列番号23と90％同一のもの;
hh.配列番号23と95％同一のもの;
ii.配列番号23と98％同一のもの;
jj.配列番号23
kk.配列番号25と90％同一のもの;
ll.配列番号25と95％同一のもの;
mm.配列番号25と98％同一のもの;及び
nn.配列番号25
からなる群から選択されるアミノ酸配列を含むポリペプチドである、構成1、2、4、6、7、8、又は10記載の方法。
（構成１２）
前記ActRIIインヒビターが、配列番号7のアミノ酸配列を含むポリペプチドである、構成1、2、4、6、7、8、又は10記載の方法。
（構成１３）
前記ActRIIインヒビターが非経口投与される、構成1、2、4、6、7、8、又は10記載の方法。
（構成１４）
前記対象が18歳未満である、構成1、2、4、6、7、8、又は10記載の方法。
（構成１５）
前記対象の身長を増加させる、構成1、2、4、6、7、8、又は10記載の方法。
（構成１６）
前記対象が末期腎疾患を有する、構成1、2、4、6、7、8、又は10記載の方法。
（構成１７）
前記対象が透析を受けている、構成1、2、4、6、7、8、又は10記載の方法。
本件出願は、以下の構成の発明を提供する。
（構成１）
対象における低回転型骨障害を治療する方法であって、治療有効量のActRIIインヒビターを、該低回転型骨障害の治療を必要とする対象に投与することを含む、前記方法。
（構成２）
対象における低回転型骨障害形態のCKD-MBDを治療する方法であって、治療有効量のActRIIインヒビターを、該低回転型骨障害形態のCKD-MBDの治療を必要とする対象に投与することを含む、前記方法。
（構成３）
前記低回転型骨障害が、石灰化した骨へのテトラサイクリン取込みの欠如を特徴とする、構成1又は2記載の方法。
（構成４）
対象における低骨代謝回転形態のCKD-MBDを治療する方法であって、治療有効量のActRIIインヒビターを、該低骨代謝回転形態のCKD-MBDの治療を必要とする対象に投与することを含む、前記方法。
（構成５）
前記低骨代謝回転形態のCKD-MBDが骨軟化症である、構成4記載の方法。
（構成６）
対象における高リン血症を特徴とする骨障害を治療する方法であって、治療有効量のActRIIインヒビターを、該高リン血症を特徴とする骨障害の治療を必要とする対象に投与することを含む、前記方法。
（構成７）
対象における血管石灰化を治療する方法であって、治療有効量のActRIIインヒビターを、アテローム性動脈硬化性石灰化の治療を必要とする対象に投与することを含む、前記方法。
（構成８）
対象における腎疾患を治療する方法であって、治療有効量のActRIIインヒビターを、該腎疾患の治療を必要とする対象に投与することを含む、前記方法。
（構成９）
前記腎疾患が腎線維症である、構成8記載の方法。
（構成１０）
血管石灰化を有すると診断された対象における血管内カルシウムレベルを低下させる方法であって、治療有効量のActRIIインヒビターを該対象に投与することを含む、前記方法。
（構成１１）
前記ActRIIインヒビターが:
a.配列番号2と90％同一のもの;
b.配列番号2と95％同一のもの;
c.配列番号2と98％同一のもの;
d.配列番号2;
e.配列番号3と90％同一のもの;
f.配列番号3と95％同一のもの;
g.配列番号3と98％同一のもの;
h.配列番号3;
i.配列番号6と90％同一のもの;
j.配列番号6と95％同一のもの;
k.配列番号6と98％同一のもの;
l.配列番号6;
m.配列番号7と90％同一のもの;
n.配列番号7と95％同一のもの;
o.配列番号7と98％同一のもの;
p.配列番号7;
q.配列番号12と90％同一のもの;
r.配列番号12と95％同一のもの;
s.配列番号12と98％同一のもの;
t.配列番号12;
u.配列番号17と90％同一のもの;
v.配列番号17と95％同一のもの;
w.配列番号17と98％同一のもの;
x.配列番号17;
y.配列番号20と90％同一のもの;
z.配列番号20と95％同一のもの;
aa.配列番号20と98％同一のもの;
bb.配列番号20;
cc.配列番号21と90％同一のもの;
dd.配列番号21と95％同一のもの;
ee.配列番号21と98％同一のもの;
ff.配列番号21
gg.配列番号23と90％同一のもの;
hh.配列番号23と95％同一のもの;
ii.配列番号23と98％同一のもの;
jj.配列番号23
kk.配列番号25と90％同一のもの;
ll.配列番号25と95％同一のもの;
mm.配列番号25と98％同一のもの;及び
nn.配列番号25
からなる群から選択されるアミノ酸配列を含むポリペプチドである、構成1、2、4、6、7、8、又は10記載の方法。
（構成１２）
前記ActRIIインヒビターが、配列番号7のアミノ酸配列を含むポリペプチドである、構成1、2、4、6、7、8、又は10記載の方法。
（構成１３）
前記ActRIIインヒビターが非経口投与される、構成1、2、4、6、7、8、又は10記載の方法。
（構成１４）
前記対象が18歳未満である、構成1、2、4、6、7、8、又は10記載の方法。
（構成１５）
前記対象の身長を増加させる、構成1、2、4、6、7、8、又は10記載の方法。
（構成１６）
前記対象が末期腎疾患を有する、構成1、2、4、6、7、8、又は10記載の方法。
（構成１７）
前記対象が透析を受けている、構成1、2、4、6、7、8、又は10記載の方法。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721898P | 2012-11-02 | 2012-11-02 | |
| US61/721,898 | 2012-11-02 | ||
| US201261740665P | 2012-12-21 | 2012-12-21 | |
| US61/740,665 | 2012-12-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540809A Division JP2016504275A (ja) | 2012-11-02 | 2013-11-01 | アクチビン−ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020098360A Division JP2020143164A (ja) | 2012-11-02 | 2020-06-05 | アクチビン−ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018168176A JP2018168176A (ja) | 2018-11-01 |
| JP2018168176A5 true JP2018168176A5 (ja) | 2018-12-27 |
| JP6714646B2 JP6714646B2 (ja) | 2020-06-24 |
Family
ID=50628091
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540809A Pending JP2016504275A (ja) | 2012-11-02 | 2013-11-01 | アクチビン−ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用 |
| JP2018125703A Expired - Fee Related JP6714646B2 (ja) | 2012-11-02 | 2018-07-02 | アクチビン−ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用 |
| JP2020098360A Pending JP2020143164A (ja) | 2012-11-02 | 2020-06-05 | アクチビン−ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用 |
| JP2022171957A Pending JP2023011741A (ja) | 2012-11-02 | 2022-10-27 | アクチビン－ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540809A Pending JP2016504275A (ja) | 2012-11-02 | 2013-11-01 | アクチビン−ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020098360A Pending JP2020143164A (ja) | 2012-11-02 | 2020-06-05 | アクチビン−ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用 |
| JP2022171957A Pending JP2023011741A (ja) | 2012-11-02 | 2022-10-27 | アクチビン－ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10195249B2 (ja) |
| EP (3) | EP3964224A1 (ja) |
| JP (4) | JP2016504275A (ja) |
| KR (3) | KR20210091358A (ja) |
| CN (1) | CN104936605A (ja) |
| AU (3) | AU2013337677B2 (ja) |
| BR (1) | BR112015009948B1 (ja) |
| CA (2) | CA3120678A1 (ja) |
| ES (2) | ES2652437T3 (ja) |
| HK (2) | HK1214525A1 (ja) |
| IL (2) | IL238443B (ja) |
| MX (2) | MX366336B (ja) |
| NZ (1) | NZ707477A (ja) |
| RU (2) | RU2678117C2 (ja) |
| WO (1) | WO2014071158A1 (ja) |
| ZA (1) | ZA201503135B (ja) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104844713B (zh) | 2005-11-23 | 2021-05-14 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| BRPI0806861A2 (pt) | 2007-02-01 | 2014-08-05 | Acceleron Pharma Inc | Antagonistas de ativina-actriia e usos para tratar ou prevenir câncer de mama |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| TWI525102B (zh) | 2007-02-09 | 2016-03-11 | 艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TWI784538B (zh) | 2008-08-14 | 2022-11-21 | 美商艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| KR20180026795A (ko) | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| EP3964224A1 (en) | 2012-11-02 | 2022-03-09 | Celgene Corporation | Activin-actrii antagonists and uses for use in treating renal disease |
| BR122023023170A2 (pt) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| ES2946160T3 (es) | 2014-12-03 | 2023-07-13 | Celgene Corp | Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico |
| ES2856001T3 (es) | 2015-04-22 | 2021-09-27 | Biogen Ma Inc | Nuevas proteínas híbridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular |
| EP4190805A3 (en) | 2015-05-20 | 2023-08-16 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| WO2017176938A1 (en) * | 2016-04-06 | 2017-10-12 | Acceleron Pharma, Inc. | Bmprii polypeptides and uses thereof |
| PT3496739T (pt) | 2016-07-15 | 2021-06-21 | Acceleron Pharma Inc | Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar |
| AU2017340504A1 (en) | 2016-10-05 | 2019-04-11 | Acceleron Pharma, Inc. | Compositions and method for treating kidney disease |
| EP3522912A4 (en) | 2016-10-05 | 2020-10-14 | Acceleron Pharma Inc. | HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES |
| US10982000B2 (en) | 2017-03-24 | 2021-04-20 | Novartis Ag | Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody |
| CN107320718B (zh) * | 2017-05-23 | 2020-12-11 | 余红 | 促生长激素释放激素激动剂在制备抗血管钙化药物中的应用 |
| JP2021522795A (ja) * | 2018-05-03 | 2021-09-02 | アクセルロン ファーマ インコーポレイテッド | ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用 |
Family Cites Families (236)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0637520B2 (ja) | 1985-07-03 | 1994-05-18 | 味の素株式会社 | ポリペプチド |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4973577A (en) | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5078486A (en) | 1989-10-13 | 1992-01-07 | Evans David W | Self-calibrating vision test apparatus |
| WO1992004913A1 (en) | 1990-09-13 | 1992-04-02 | Children's Hospital Medical Center Of Northern California | Method for increasing red blood cell production by treatment with activin or activin-related peptides |
| US5208219A (en) | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
| US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| JPH06500574A (ja) | 1991-05-10 | 1994-01-20 | ザ ソーク インスティテュート フォア バイオロジカル スタディーズ | アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生 |
| US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| KR100255415B1 (ko) | 1991-06-25 | 2000-05-01 | 브루스 엠. 에이센 | 비엠피-9 조성물 |
| US6692925B1 (en) | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
| EP1475440A3 (en) | 1993-01-12 | 2004-11-17 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-3 |
| CA2161807A1 (en) | 1993-05-12 | 1994-11-24 | Anthony J. Celeste | Bmp-10 compositions |
| US5637480A (en) | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5831050A (en) | 1993-06-07 | 1998-11-03 | Creative Biomolecules, Inc. | Morphogen cell surface receptor |
| ATE355369T1 (de) | 1993-10-14 | 2006-03-15 | Harvard College | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5658876A (en) | 1994-04-28 | 1997-08-19 | The General Hospital Corporation | Activin antagonists as novel contraceptives |
| ES2251721T3 (es) | 1994-07-08 | 2006-05-01 | The Johns Hopkins University School Of Medicine | Factor-11 de diferenciacion del crecimiento. |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5545616A (en) | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| US5760010A (en) | 1995-01-01 | 1998-06-02 | Klein; Ira | Method of treating liver disorders with a macrolide antibiotic |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| ATE352638T1 (de) | 1995-04-11 | 2007-02-15 | Gen Hospital Corp | REVERSE ßTWO-HYBRIDß-SYSTEME |
| EP0771873A3 (en) | 1995-10-27 | 1998-03-04 | Takeda Chemical Industries, Ltd. | Neuronal cell-specific receptor protein |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US20050244867A1 (en) | 1996-03-26 | 2005-11-03 | Human Genome Sciences, Inc. | Growth factor HTTER36 |
| US6004780A (en) | 1996-03-26 | 1999-12-21 | Human Genome Sciences, Inc. | Growth factor HTTER36 |
| PL189756B1 (pl) | 1996-10-25 | 2005-09-30 | Searle & Co | Polipeptyd ludzkiego agonisty receptora erytropoetyny (EPO), sposób jego wytwarzania i zastosowanie, cząsteczka kwasu nukleinowego, kompozycja, sposób selektywnego namnażania ex vivo erytroidalnych komórek progenitorowych |
| US6605699B1 (en) | 1997-01-21 | 2003-08-12 | Human Genome Sciences, Inc. | Galectin-11 polypeptides |
| US6034062A (en) | 1997-03-13 | 2000-03-07 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-9 compositions and their uses |
| US6231880B1 (en) | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| EP1007673B1 (en) | 1997-07-30 | 2008-12-17 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| AU8921698A (en) | 1997-08-29 | 1999-03-16 | Human Genome Sciences, Inc. | Follistatin-3 |
| US6953662B2 (en) | 1997-08-29 | 2005-10-11 | Human Genome Sciences, Inc. | Follistatin-3 |
| US7052873B2 (en) | 1997-10-03 | 2006-05-30 | Chugai Seiyaku Kabushiki Kaisha | Natural human antibody |
| US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| BR9913857A (pt) | 1998-09-17 | 2001-06-12 | Lilly Co Eli | Formulações de proteìna |
| DE69934995T2 (de) | 1998-09-22 | 2007-11-22 | Long Yu | Für den menschlichen wachstums-differenzierungsfaktor kodierende sequenz und polypeptid, welches durch solche dna-sequenz kodiert wird und verfahren zur herstellung |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6548634B1 (en) | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
| US6238860B1 (en) | 1998-11-05 | 2001-05-29 | Dyax Corp. | Binding moieties for human parvovirus B19 |
| US6777205B1 (en) | 1998-11-06 | 2004-08-17 | Sterrenbeld Biotechnologie North America, Inc. | Host cells expressing recombinant human erythropoietin |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| MXPA01007366A (es) | 1999-01-21 | 2002-06-04 | Metamorphix Inc | Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos. |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| CA2365449A1 (en) | 1999-04-19 | 2000-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Inhibitor of the growth of androgen-independent tumor |
| US6468543B1 (en) | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| CA2390292A1 (en) | 1999-11-12 | 2001-05-25 | Maxygen Holdings Ltd. | Interferon gamma conjugates |
| WO2001043763A1 (en) | 1999-12-15 | 2001-06-21 | Research Development Foundation | Betaglycan as an inhibin receptor and uses thereof |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| BRPI0110914B8 (pt) | 2000-05-15 | 2021-05-25 | Hoffmann La Roche | 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica' |
| US6627424B1 (en) | 2000-05-26 | 2003-09-30 | Mj Bioworks, Inc. | Nucleic acid modifying enzymes |
| AU2001269709A1 (en) | 2000-07-19 | 2002-02-05 | Eli Lilly And Company | Nucleic acids, vectors, host cells, polypeptides, and uses thereof |
| US6632180B1 (en) | 2000-09-07 | 2003-10-14 | John H. Laragh | Method for evaluating and treating hypertension |
| DE10045591A1 (de) | 2000-09-15 | 2002-04-04 | Klaus Pfizenmaier | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| WO2002040501A2 (en) | 2000-11-20 | 2002-05-23 | The Board Of Trustees Of The University Of Illinois | Membrane scaffold proteins |
| US20030082233A1 (en) | 2000-12-01 | 2003-05-01 | Lyons Karen M. | Method and composition for modulating bone growth |
| EP1370287A2 (en) | 2000-12-01 | 2003-12-17 | Wyeth | Method and composition for modulating bone growth |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US20040132675A1 (en) | 2002-02-08 | 2004-07-08 | Calvin Kuo | Method for treating cancer and increasing hematocrit levels |
| US7294472B2 (en) | 2001-03-14 | 2007-11-13 | Caden Biosciences | Method for identifying modulators of G protein coupled receptor signaling |
| WO2002074340A1 (fr) | 2001-03-16 | 2002-09-26 | Takeda Chemical Industries, Ltd. | Procede de fabrication d'une preparation a liberation continue |
| US20030082630A1 (en) | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
| KR20040030628A (ko) | 2001-05-24 | 2004-04-09 | 지모제넥틱스, 인코포레이티드 | Ｔａｃｉ-면역글로불린 융합 단백질 |
| EP1390497A2 (en) | 2001-05-25 | 2004-02-25 | Genset | Human cdnas and proteins and uses thereof |
| AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| US6855344B2 (en) | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| ATE448481T1 (de) | 2001-07-17 | 2009-11-15 | Teijin Ltd | Selektionsverfahren für eine durch das austesten einer ppard aktivierenden wirkung charakterisierten substanz und arzneistoff |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| US20030153503A1 (en) | 2001-12-06 | 2003-08-14 | Klaus Stephen J. | Methods of increasing endogenous erythropoietin (EPO) |
| US20060234918A1 (en) | 2001-12-19 | 2006-10-19 | Voyager Pharmaceutical Corporation | Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors |
| US20030144203A1 (en) | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
| US6998118B2 (en) | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
| WO2003068801A2 (en) | 2002-02-11 | 2003-08-21 | Genentech, Inc. | Antibody variants with faster antigen association rates |
| CA2476887A1 (en) | 2002-02-21 | 2003-09-04 | Wyeth | Gasp1:a follistatin domain containing protein |
| PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| US20030219846A1 (en) | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| WO2003087162A2 (en) | 2002-04-18 | 2003-10-23 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| BR0313729A (pt) | 2002-08-16 | 2005-06-21 | Wyeth Corp | Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo |
| BR0315316A (pt) | 2002-10-15 | 2005-08-16 | Celgene Corp | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| AU2002953327A0 (en) | 2002-12-12 | 2003-01-09 | Monash University | Methods of diagnosing prognosing and treating activin associated diseases and conditions |
| WO2004064770A2 (en) | 2003-01-17 | 2004-08-05 | Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services | Use of smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney |
| AU2004210193B2 (en) | 2003-02-07 | 2007-07-12 | Prometic Pharma Smt Limited | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis |
| WO2004086953A2 (en) | 2003-03-26 | 2004-10-14 | The Board Of Trustees Of The University Of Arkansas | Method for diagnosis and treatment of bone turnover |
| US20070184052A1 (en) | 2003-05-09 | 2007-08-09 | Lin Herbert Y | Soluble tgf-b type III receptor fusion proteins |
| UA85055C2 (ru) | 2003-06-02 | 2008-12-25 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| JP4688802B2 (ja) | 2003-06-16 | 2011-05-25 | セルテック アール アンド ディー， インコーポレイテッド | 骨の鉱化作用を増大させるためのスクレロスチンに特異的な抗体および方法 |
| US7611465B2 (en) * | 2003-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Rapid and accurate detection of bone quality using ultrasound critical angle reflectometry |
| WO2005009460A2 (en) | 2003-07-25 | 2005-02-03 | Medexis, S.A. | Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer |
| DE10335211A1 (de) | 2003-08-01 | 2005-02-17 | Robert Bosch Gmbh | Kraftstoff-Einspritzvorrichtung für eine Brennkraftmaschine |
| US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
| US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| WO2005070967A2 (en) | 2004-01-22 | 2005-08-04 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
| US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| WO2005094871A2 (en) | 2004-03-26 | 2005-10-13 | Acceleron Pharma Inc. | Bmp-3 propeptides and related methods |
| CA2561809A1 (en) | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
| WO2005113590A2 (en) | 2004-05-12 | 2005-12-01 | Acceleron Pharma Inc. | Bmp10 propeptides and related methods |
| WO2006002387A2 (en) | 2004-06-24 | 2006-01-05 | Acceleron Pharma Inc. | Gdf3 propeptides and related methods |
| EP2314617B1 (en) | 2004-07-23 | 2015-06-24 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
| JP2008508878A (ja) | 2004-08-05 | 2008-03-27 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 細胞の発生および機能に対する効果を有する分子 |
| US20060034831A1 (en) | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| WO2006039400A2 (en) | 2004-09-29 | 2006-04-13 | Mount Sinai School Of Medicine Of New York University | Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
| US7879569B2 (en) | 2004-11-09 | 2011-02-01 | The Trustees Of The University Of Pennsylvania | Methods for diagnosis of myelodysplastic syndromes (MDS) |
| US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| US7968091B2 (en) | 2005-02-16 | 2011-06-28 | The General Hospital Corporation | Methods and compositions to regulate iron metabolism |
| EP1884235A1 (en) | 2005-04-26 | 2008-02-06 | Ajinomoto Co., Inc. | Myeloerythroid progenitor differentiation inducer |
| JP2007099764A (ja) | 2005-09-09 | 2007-04-19 | Ajinomoto Co Inc | 血糖低下剤 |
| CA2621623A1 (en) | 2005-09-28 | 2007-04-05 | Zymogenetics, Inc. | Il-17a and il-17f antagonists and methods of using the same |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| CN104844713B (zh) * | 2005-11-23 | 2021-05-14 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| JP2009518422A (ja) | 2005-12-06 | 2009-05-07 | アムジェン インコーポレイテッド | ミオスタチン・アンタゴニストの使用 |
| CA2632936A1 (en) | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US20070161578A1 (en) | 2005-12-21 | 2007-07-12 | Hwa Joyce J | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist |
| WO2007076127A2 (en) | 2005-12-22 | 2007-07-05 | Biogen Idec Ma Inc | Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators |
| US7361510B2 (en) | 2006-01-20 | 2008-04-22 | Beckman Coulter, Inc. | Methods of detection of iron deficiency |
| EP1976377A4 (en) | 2006-01-25 | 2010-06-23 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| ATE530066T1 (de) | 2006-02-28 | 2011-11-15 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
| US8008074B2 (en) * | 2006-03-20 | 2011-08-30 | The Uab Research Foundation | Compositions and methods for improving bone mass through modulation of receptors of PTH and fragments thereof |
| EP2007813A2 (en) | 2006-04-14 | 2008-12-31 | Amgen Inc. | Agonist erythropoietin receptor antibodies |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| WO2007133653A2 (en) | 2006-05-09 | 2007-11-22 | Hemaquest Pharmaceuticals, Inc. | Methods for treating blood disorders |
| EP2048948B1 (en) | 2006-07-21 | 2012-02-29 | Lyne Laboratories, Inc. | Liquid compositions of calcium acetate |
| GB0615129D0 (en) | 2006-07-29 | 2006-09-06 | Univ Cardiff | Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| JP5468187B2 (ja) | 2006-09-26 | 2014-04-09 | ポリプラスチックス株式会社 | ポリアセタール樹脂組成物 |
| WO2008060139A1 (en) | 2006-11-17 | 2008-05-22 | Erasmus University Medical Center Rotterdam | Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein |
| WO2008073292A2 (en) | 2006-12-08 | 2008-06-19 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn) |
| EP2103628A4 (en) | 2006-12-14 | 2012-02-22 | Forerunner Pharma Res Co Ltd | MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY |
| BRPI0720476B1 (pt) * | 2006-12-18 | 2022-05-31 | Acceleron Pharma Inc | Uso de um polipeptídeo de actrii para tratar anemia em um paciente humano |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| BRPI0806861A2 (pt) | 2007-02-01 | 2014-08-05 | Acceleron Pharma Inc | Antagonistas de ativina-actriia e usos para tratar ou prevenir câncer de mama |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| TWI525102B (zh) | 2007-02-09 | 2016-03-11 | 艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| EP2150560A1 (en) | 2007-06-01 | 2010-02-10 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| WO2009009059A1 (en) | 2007-07-09 | 2009-01-15 | Biogen Idec Ma Inc. | Spiro compounds as antagonists of tgf-beta |
| JP2010535708A (ja) | 2007-08-03 | 2010-11-25 | ビオマリン アイジーエー リミテッド | デュシェンヌ型筋ジストロフィーの治療のための薬物併用 |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| GB0715938D0 (en) | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment of duchenne muscular dystrophy |
| WO2009025651A1 (en) | 2007-08-17 | 2009-02-26 | University Of Maine System Board Of Trustees | Biologically active peptide and method of using the same |
| WO2009035629A1 (en) | 2007-09-13 | 2009-03-19 | Ludwig Institute Of Cancer Research | Method for modifying cellular immune response by modulating activin activity |
| CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| WO2009070243A2 (en) | 2007-11-21 | 2009-06-04 | Amgen Inc. | Wise binding agents and epitopes |
| JP5638961B2 (ja) * | 2008-03-13 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | Ｂｍｐシグナル伝達経路のインヒビター |
| WO2009146148A2 (en) | 2008-04-04 | 2009-12-03 | Tactair Fluid Controls, Inc. | Locking mechanism with bi-modal actuator |
| WO2009137075A1 (en) | 2008-05-06 | 2009-11-12 | Acceleron Pharma Inc. | Anti-activin antibodies and uses for promoting bone growth |
| WO2009137613A2 (en) | 2008-05-06 | 2009-11-12 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| JP2011521969A (ja) | 2008-05-30 | 2011-07-28 | スムマ ヘルス システムズ エルエルシー | 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 |
| US20100015144A1 (en) | 2008-06-26 | 2010-01-21 | Acceleron Pharma Inc. | Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
| DK2318028T3 (da) | 2008-06-26 | 2020-05-04 | Acceleron Pharma Inc | Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer |
| US8637611B2 (en) | 2008-08-13 | 2014-01-28 | Designer Molecules, Inc. | Amide-extended crosslinking compounds and methods for use thereof |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TWI784538B (zh) | 2008-08-14 | 2022-11-21 | 美商艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| WO2010059861A1 (en) | 2008-11-20 | 2010-05-27 | University Of Southern California | Compositions and methods to modulate hair growth |
| EA201791940A3 (ru) | 2008-11-26 | 2018-04-30 | Амген Инк. | Варианты полипептидов рецептора iib активина и их использование |
| WO2010083034A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| CA2750559A1 (en) * | 2009-02-05 | 2010-08-12 | Digna Biotech, S.L. | Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides |
| US8110355B2 (en) | 2009-02-20 | 2012-02-07 | GenRemedy, LLC | Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis |
| EP2419105A4 (en) | 2009-04-17 | 2012-09-12 | Summa Health Systems Llc | USE OF TRANSFORMATION OF GROWTH FACTOR B RECEPTOR INHIBITORS TO SUPPRESS OCULAR HEALING |
| NO2424895T3 (ja) | 2009-04-27 | 2018-02-03 | ||
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| KR20180026795A (ko) | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| EP3838919A1 (en) | 2009-08-13 | 2021-06-23 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
| CA2773494A1 (en) | 2009-09-09 | 2011-03-17 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof |
| JP5836961B2 (ja) | 2009-11-03 | 2015-12-24 | アクセルロン ファーマ， インコーポレイテッド | 脂肪肝疾患を処置するための方法 |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| JP6472999B2 (ja) | 2011-07-01 | 2019-02-20 | ノバルティス アーゲー | 代謝障害を治療するための方法 |
| EP3875104A1 (en) | 2011-10-17 | 2021-09-08 | Acceleron Pharma Inc. | Compositions for treating myelofibrosis |
| WO2013063536A1 (en) | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| WO2013059876A1 (en) | 2011-10-28 | 2013-05-02 | Paranta Biosciences Limited | A method of treating mucus hypersecretion |
| EP2793925B1 (en) | 2011-12-19 | 2019-03-20 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| CA2868466A1 (en) | 2012-03-30 | 2013-10-03 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of iduronate-2-sulfatase |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9663569B2 (en) | 2012-06-14 | 2017-05-30 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases |
| KR102143476B1 (ko) | 2012-07-02 | 2020-08-12 | 쿄와 기린 가부시키가이샤 | 항ｂｍｐ９ 항체를 유효 성분으로 하는, 신장성 빈혈, 암성 빈혈 등의 빈혈에 대한 치료제 |
| EP3527219A1 (en) | 2012-10-24 | 2019-08-21 | Celgene Corporation | Methods for treating anemia |
| ES2753811T3 (es) | 2012-10-24 | 2020-04-14 | Celgene Corp | Biomarcador para uso en el tratamiento de anemia |
| WO2014064292A1 (en) | 2012-10-26 | 2014-05-01 | Universite Pierre Et Marie Curie (Paris 6) | A method for preventing or treating atrial fibrillation |
| EP3964224A1 (en) | 2012-11-02 | 2022-03-09 | Celgene Corporation | Activin-actrii antagonists and uses for use in treating renal disease |
| CN104884049A (zh) | 2012-11-08 | 2015-09-02 | 克莱尔塞德生物医学股份有限公司 | 用于在人类受试者中治疗眼部疾病的方法和装置 |
| CN103047581B (zh) | 2012-12-04 | 2015-04-01 | 京东方科技集团股份有限公司 | 背光模组及具有该背光模组的显示装置 |
| US20150328249A1 (en) | 2012-12-11 | 2015-11-19 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Modulation of myofiber repair by anti-myostatin strategies and/or ppar gamma ligands, alone or in combination with stem cells, for the therapy of critical limb ischemia and other ischemic processes affecting the skeletal muscle |
| US20140220033A1 (en) | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| TN2016000057A1 (en) | 2013-08-14 | 2017-07-05 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
| JP2017505428A (ja) | 2013-12-16 | 2017-02-16 | パランタ バイオサイエンス リミテッド | 診断及び治療の方法 |
| EP3094751A4 (en) | 2014-01-14 | 2017-06-07 | Santa Maria Biotherapeutics, Inc. | Activin inhibitor response prediction and uses for treatment |
| WO2015111008A2 (en) | 2014-01-27 | 2015-07-30 | Novartis Ag | Biomarkers predictive of muscle atrophy, method and use |
| MA39722A (fr) | 2014-03-21 | 2021-06-02 | Acceleron Pharma Inc | Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 |
| US10260068B2 (en) | 2014-03-31 | 2019-04-16 | Sumitomo Dainippon Pharma Co., Ltd. | Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva |
| MX2016013635A (es) | 2014-04-18 | 2017-02-02 | Acceleron Pharma Inc | Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes. |
| TW201622746A (zh) | 2014-04-24 | 2016-07-01 | 諾華公司 | 改善或加速髖部骨折術後身體復原之方法 |
| JP2017519009A (ja) | 2014-06-13 | 2017-07-13 | サンタ マリア バイオセラピューティクス インコーポレイテッド | 製剤化された受容体ポリペプチドおよび関連する方法 |
| BR122023023170A2 (pt) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| ES2946160T3 (es) | 2014-12-03 | 2023-07-13 | Celgene Corp | Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| CN107847562A (zh) | 2015-05-13 | 2018-03-27 | 细胞基因公司 | 使用 ACTRII 配体陷阱治疗 β‑地中海贫血 |
| EP4190805A3 (en) | 2015-05-20 | 2023-08-16 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| WO2017079591A2 (en) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| EP3380121B1 (en) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
| AU2017302282A1 (en) | 2016-07-27 | 2019-02-07 | Acceleron Pharma Inc. | Methods and compositions for treating myelofibrosis |
-
2013
- 2013-11-01 EP EP21179133.0A patent/EP3964224A1/en not_active Withdrawn
- 2013-11-01 KR KR1020217021923A patent/KR20210091358A/ko active Application Filing
- 2013-11-01 EP EP17190589.6A patent/EP3308796B1/en active Active
- 2013-11-01 ES ES13851864.2T patent/ES2652437T3/es active Active
- 2013-11-01 AU AU2013337677A patent/AU2013337677B2/en not_active Ceased
- 2013-11-01 CA CA3120678A patent/CA3120678A1/en active Pending
- 2013-11-01 EP EP13851864.2A patent/EP2914277B1/en active Active
- 2013-11-01 BR BR112015009948-3A patent/BR112015009948B1/pt active IP Right Grant
- 2013-11-01 KR KR1020157014476A patent/KR102279522B1/ko active IP Right Grant
- 2013-11-01 CA CA2890217A patent/CA2890217C/en active Active
- 2013-11-01 ES ES17190589T patent/ES2884095T3/es active Active
- 2013-11-01 RU RU2015120804A patent/RU2678117C2/ru active
- 2013-11-01 NZ NZ70747713A patent/NZ707477A/en unknown
- 2013-11-01 US US14/438,146 patent/US10195249B2/en active Active
- 2013-11-01 JP JP2015540809A patent/JP2016504275A/ja active Pending
- 2013-11-01 CN CN201380069246.8A patent/CN104936605A/zh active Pending
- 2013-11-01 WO PCT/US2013/068009 patent/WO2014071158A1/en active Application Filing
- 2013-11-01 RU RU2018145985A patent/RU2018145985A/ru unknown
- 2013-11-01 KR KR1020227039730A patent/KR20220156979A/ko not_active Application Discontinuation
- 2013-11-01 MX MX2015005538A patent/MX366336B/es active IP Right Grant
-
2015
- 2015-04-22 IL IL238443A patent/IL238443B/en active IP Right Grant
- 2015-04-30 MX MX2019008085A patent/MX2019008085A/es unknown
- 2015-05-07 ZA ZA2015/03135A patent/ZA201503135B/en unknown
-
2016
- 2016-03-07 HK HK16102559.1A patent/HK1214525A1/zh not_active IP Right Cessation
-
2018
- 2018-07-02 JP JP2018125703A patent/JP6714646B2/ja not_active Expired - Fee Related
- 2018-09-24 AU AU2018236696A patent/AU2018236696A1/en not_active Abandoned
- 2018-10-15 HK HK18113150.9A patent/HK1254086A1/zh unknown
-
2019
- 2019-01-02 US US16/238,351 patent/US20190262423A1/en not_active Abandoned
- 2019-06-03 IL IL267066A patent/IL267066B/en unknown
-
2020
- 2020-06-05 JP JP2020098360A patent/JP2020143164A/ja active Pending
- 2020-08-07 AU AU2020213397A patent/AU2020213397A1/en not_active Abandoned
-
2022
- 2022-10-27 JP JP2022171957A patent/JP2023011741A/ja active Pending
-
2023
- 2023-01-18 US US18/156,015 patent/US20230293634A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018168176A5 (ja) | ||
| JP2016504275A5 (ja) | ||
| JP2020143164A5 (ja) | ||
| RU2015120804A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| JP2019031567A5 (ja) | ||
| Hellmich et al. | Embryonic expression of glial cell-line derived neurotrophic factor (GDNF) suggests multiple developmental roles in neural differentiation and epithelial-mesenchymal interactions | |
| JP2015502346A5 (ja) | ||
| JP2017533191A5 (ja) | ||
| JP2009544279A5 (ja) | ||
| JP2018127467A5 (ja) | ||
| JP2019523295A5 (ja) | ||
| JP2016528207A5 (ja) | ||
| JP2019529350A5 (ja) | ||
| JP2010514839A5 (ja) | ||
| JP2019504112A5 (ja) | ||
| RU2017101705A (ru) | Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii | |
| JP2010202664A5 (ja) | ||
| JPWO2019156137A5 (ja) | ||
| EA200700273A1 (ru) | Способ лечения гиперфосфатемии c использованием гидроксикарбоната лантана | |
| JP2017519768A5 (ja) | ||
| JP2017521074A5 (ja) | ||
| AU2021203523A1 (en) | Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator | |
| JP2020524696A5 (ja) | ||
| JP2019162119A5 (ja) | ||
| JP2005506275A5 (ja) |